CD274 and non-small cell lung carcinoma: Owing to phase III clinical trials, such as Keynotes 024 and 042, the initial standard therapy for patients with advanced NSCLC with PD-L1 positive tumors has shifted from cytotoxic agents to PD-1 inhibitors [10, 16].